ADAM17 and COVID-19: On the other hand, ADAM17 cellular activity has been shown to be positively regulated by epidermal growth factor receptor (EGFR) signalling,8 thus raising the question of the impact of anti-EGFR tyrosine kinase inhibitors (TKI) on COVID-19 susceptibility through ADAM17 down-tuning (Fig. 1).